Home-Based System Relieves Cirrhosis Refractory Ascites
|
By HospiMedica International staff writers Posted on 11 Jan 2022 |

Image: An ascites patient with abdominal paracentesis scars (Photo courtesy of iStock)
A novel tunneled peritoneal catheter (PeCa) drainage system provided significant relief for patients with refractory ascites, according to a new study.
The PeCa implant, developed at Hannover Medical School (Germany), is composed of internal shut that lies in the peritoneal cavity, a tunneled section that passes through subcutaneous tissue, and an external port to which drainage bags are connected. To test system efficacy, outcomes in 152 patients with refractory ascites, who were not candidates for transjugular intrahepatic portosystemic shunt (TIPS) and received a PeCa implant, were compared to 71 patients who received standard care, which included repeated large volume paracentesis and albumin.
The results revealed that factors associated with 90-day survival were PeCa implantation, and each point of Model for End-Stage Liver Disease (MELD) score. Hospitalizations were more common in the PeCa group, for reasons that included spontaneous bacterial peritonitis (SBP), hyponatremia, and infections other than SBP. There was no significant difference in mortality between the two groups, but there were trends in the PeCa group towards higher frequency of acute kidney injury (AKI). The study was presented at the American Association for the Study of Liver Diseases annual conference, held online during November 2021.
“Patients with refractory ascites have a very high risk for rehospitalization, AKI, and death. Our data indicate that PeCa could be a valuable new treatment option for patients with refractory ascites and contraindication for TIPS,” said study co-author and presenter Tammo Lambert Tergast, MD. “I think if we can optimize the treatment after discharge, we can also minimize the rehospitalization in these patients. However, the risk for hyponatremia and AKI has to be considered and further explored.”
Refractory ascites occurs when patients no longer respond to medical therapy, a condition that affects over 100,000 patients in Europe and the United States every year, a number that is growing at approximately 10% a year. The primary treatment for ascites is paracentesis, a procedure in which a large bore needle is inserted into the patient's abdomen to remove between 5‐10 liters of ascites that has accumulated over a period of a week or two.
Related Links:
Hannover Medical School
The PeCa implant, developed at Hannover Medical School (Germany), is composed of internal shut that lies in the peritoneal cavity, a tunneled section that passes through subcutaneous tissue, and an external port to which drainage bags are connected. To test system efficacy, outcomes in 152 patients with refractory ascites, who were not candidates for transjugular intrahepatic portosystemic shunt (TIPS) and received a PeCa implant, were compared to 71 patients who received standard care, which included repeated large volume paracentesis and albumin.
The results revealed that factors associated with 90-day survival were PeCa implantation, and each point of Model for End-Stage Liver Disease (MELD) score. Hospitalizations were more common in the PeCa group, for reasons that included spontaneous bacterial peritonitis (SBP), hyponatremia, and infections other than SBP. There was no significant difference in mortality between the two groups, but there were trends in the PeCa group towards higher frequency of acute kidney injury (AKI). The study was presented at the American Association for the Study of Liver Diseases annual conference, held online during November 2021.
“Patients with refractory ascites have a very high risk for rehospitalization, AKI, and death. Our data indicate that PeCa could be a valuable new treatment option for patients with refractory ascites and contraindication for TIPS,” said study co-author and presenter Tammo Lambert Tergast, MD. “I think if we can optimize the treatment after discharge, we can also minimize the rehospitalization in these patients. However, the risk for hyponatremia and AKI has to be considered and further explored.”
Refractory ascites occurs when patients no longer respond to medical therapy, a condition that affects over 100,000 patients in Europe and the United States every year, a number that is growing at approximately 10% a year. The primary treatment for ascites is paracentesis, a procedure in which a large bore needle is inserted into the patient's abdomen to remove between 5‐10 liters of ascites that has accumulated over a period of a week or two.
Related Links:
Hannover Medical School
Latest Patient Care News
- Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
- Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
- VR Training Tool Combats Contamination of Portable Medical Equipment
- Portable Biosensor Platform to Reduce Hospital-Acquired Infections
- First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
- Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

- Game-Changing Innovation in Surgical Instrument Sterilization Significantly Improves OR Throughput
- Next Gen ICU Bed to Help Address Complex Critical Care Needs
- Groundbreaking AI-Powered UV-C Disinfection Technology Redefines Infection Control Landscape
- Clean Hospitals Can Reduce Antibiotic Resistance, Save Lives
- Smart Hospital Beds Improve Accuracy of Medical Diagnosis
- New Fast Endoscope Drying System Improves Productivity and Traceability
- World’s First Automated Endoscope Cleaner Fights Antimicrobial Resistance
- Portable High-Capacity Digital Stretcher Scales Provide Precision Weighing for Patients in ER
- Portable Clinical Scale with Remote Indicator Allows for Flexible Patient Weighing Use
- Innovative and Highly Customizable Medical Carts Offer Unlimited Configuration Possibilities
Channels
Artificial Intelligence
view channel
AI Model Uses Eye Imaging to Identify Risk of Major Systemic Diseases
Early detection of systemic disease risk remains a persistent challenge in population health screening. Cardiometabolic conditions such as diabetes, heart disease, and stroke often progress without symptoms... Read more
AI Platform Interprets Real-Time Wearable Data for Parkinson’s Management
Parkinson’s disease presents fluctuating motor and non-motor symptoms that complicate day-to-day self-management and clinical decision-making. Care teams require timely, longitudinal insight into medication... Read moreCritical Care
view channel
Bacteria-Resistant Urinary Catheter Coating Reduces Infections and Antibiotic Use
Catheter-associated urinary tract infections (CAUTIs) are a major hospital-acquired infection, responsible for about 75% of urinary tract infections acquired in hospitals. They increase morbidity and drive... Read more
Sensor-Integrated Airway Stent Enables Continuous Remote Monitoring
Patients with airway stents require vigilant follow‑up to detect obstruction, migration, or tissue overgrowth that can develop without warning. Surveillance often relies on intermittent bronchoscopy, which... Read more
Vibration-Based Tools Aim to Improve Newborn Screening for Heart Defects
Critical congenital heart diseases are life-threatening structural heart defects present at birth. Early recognition is essential because affected infants require medication or surgery within the first year of life.... Read moreSurgical Techniques
view channel
Dual-Energy Ablation and Conduction System Pacing Show Positive Early Outcomes
Atrial fibrillation and other arrhythmias are common in both hospitalized and ambulatory patients, often complicating hemodynamic stability, stroke prevention, and perioperative care. Within this context,... Read more
Torqueable Microcatheters Enhance Navigation in Complex Coronary Lesions
Interventional cardiologists frequently encounter tortuous vessels and heavily calcified or fibrotic coronary lesions that complicate guidewire control and device delivery. Stable, predictable torque and... Read more
Transcatheter Venous Arterialization Improves Outcomes in No-Option Limb Ischemia Patients
Chronic limb-threatening ischemia (CLTI) is an advanced stage of peripheral artery disease in which plaque narrows leg arteries and severely restricts blood flow, leading to pain, nonhealing wounds, and... Read moreHealth IT
view channel
AI System Detects and Quantifies Chronic Subdural Hematoma
Viz.ai (San Francisco, CA, USA) announced a strategic commercialization collaboration with Johnson & Johnson (New Brunswick, NJ, USA) to expand access in the United States to the Viz Subdural solution... Read more
Continuous Monitoring Platform Detects Infection Risk Across Care Transitions
Patients leaving skilled nursing facilities often lose continuous physiologic monitoring, increasing the risk of undetected infection and delayed intervention. Nursing home residents are seven times more... Read more
Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings
Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read morePoint of Care
view channelBusiness
view channel
Johnson & Johnson Launches AI-Driven Cardiac Mapping System
Johnson & Johnson has introduced the CARTOSOUND SONATA Module for the CARTO System at the Heart Rhythm Society (HRS) 2026 meeting in Chicago. The module uses artificial intelligence with the CARTO... Read more







